Streetbeat News

Price Targets

BRPHF

HIVE

HUT

MSTR

MicroStrategy Inc. (NASDAQ:MSTR) is considered overvalued by 26% according to 10x Research's Markus Thielen, who suggests it's time to take profit based on a regression model linking MSTR stock to Bitcoin prices. Thielen predicts Bitcoin to reach $45,000 by Christmas. Other crypto-related stocks like HIVE Digital Technologies Ltd (NASDAQ:HIVE), HUT 8 Corp (NASDAQ:HUT), and Galaxy Digital Holdings Ltd (OTC:BRPHF) also saw significant year-to-date surges. MicroStrategy recently increased its Bitcoin holdings, now owning 189,150 Bitcoin worth $5.9 billion. Max Keiser hinted at a potential $5 billion mixed debt & equity shelf offering by MicroStrategy, possibly to buy more Bitcoin.

Portfolio Pulse from Khyathi Dalal

December 28, 2023 | 5:46 pm

RMBS

Rosenblatt analyst Kevin Cassidy has reiterated a Buy rating on Rambus (NASDAQ:RMBS) and maintained the $85 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 5:38 pm

CRON

B of A Securities has maintained its Underperform rating for Cronos Group (NASDAQ:CRON) but raised its price target from $1.78 to $2.00. Cronos Group's shares are currently trading at $2.05, which is slightly above the new target. The revised target suggests a potential downside of 2.44% from the current trading price. Cronos Group is involved in the cultivation and sale of medicinal and recreational cannabis, with operations primarily in Canada and export activities to Israel.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 5:00 pm

PSA

Truist Securities has reaffirmed its Buy rating on Public Storage (NYSE:PSA) and increased its price target from $285.00 to $315.00. Public Storage's stock is currently trading at $305.78, up 0.16% from the previous day. The new price target suggests a potential upside of 3.02% from the current price. Public Storage is the largest owner of self-storage facilities in the U.S. and has interests in the European market through Shurgard Self Storage.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 5:00 pm

SEE

Mizuho has maintained a Neutral rating for Sealed Air (NYSE:SEE) and increased its price target from $36.00 to $40.00. Sealed Air's shares are currently trading at $36.34, and the new price target suggests a potential upside of 10.07%. Sealed Air operates in food packaging and industrial/e-commerce packaging solutions.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 5:00 pm

CERE

JP Morgan has maintained a Neutral rating for Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) but raised its price target from $25.00 to $45.00. Cerevel's shares are currently trading at $42.50, and the new price target suggests a potential upside of 5.88%. Cerevel focuses on developing treatments for neuroscience diseases with a diversified pipeline of clinical and preclinical therapies.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 5:00 pm

MTCH

Keybanc has maintained its Overweight rating on Match Group (NASDAQ:MTCH) but reduced its price target from $56.00 to $48.00. Match Group's shares are currently trading at $35.82, and the new price target suggests a potential upside of 34.0%. Match Group, known for its portfolio of online dating services including Tinder and OkCupid, generates most of its revenue from user fees.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 5:00 pm

BCTX

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on BriaCell Therapeutics (NASDAQ:BCTX) and maintained an $18 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 28, 2023 | 4:30 pm

QUAL

QUS

SPHQ

State Street Global Advisors recommends quality U.S. equities for gains in 2024, despite challenges like high interest rates and soft demand outlook. They suggest that high-quality companies with stable earnings and strong balance sheets will outperform. Three ETFs to consider are SPDR MSCI USA Strategic Factors ETF (QUS), iShares MSCI USA Quality Factor ETF (QUAL), and Invesco S&P 500 Quality ETF (SPHQ), which focus on quality-centric upside with a defensive bias.

Portfolio Pulse from Surbhi Jain

December 28, 2023 | 3:14 pm

NEO

Seven analysts have recently updated their ratings on NeoGenomics (NASDAQ:NEO), with a mix of bullish and indifferent stances. The average 12-month price target is now $18.14, down from the previous $19.00. Analysts from firms including Needham, Morgan Stanley, Goldman Sachs, and Piper Sandler have maintained or adjusted their ratings and price targets. NeoGenomics operates cancer-focused genetic testing labs and has shown a revenue growth of 17.99% as of September 30, 2023, but struggles with net margin and ROE. The company's debt-to-equity ratio is below industry average, indicating less reliance on debt.

Portfolio Pulse from Benzinga Insights

December 28, 2023 | 3:00 pm